TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03474016

Intervention type: DIAGNOSTIC_TEST
Intervention: Mammography-Histopathological examination of breast mass specimens- polymerase chain reaction
Description: Mammography-Histopathological examination of breast mass specimens-Detection of long and short DNA fragments in serum using real-time quantitative polymerase chain reaction

Intervention type: DIAGNOSTIC_TEST
Intervention: Mammography-Histopathological examination of breast mass specimens- polymerase chain reaction
Description: Mammography-Histopathological examination of breast mass specimens-Detection of long and short DNA fragments in serum using real-time quantitative polymerase chain reaction

Intervention type: DIAGNOSTIC_TEST
Intervention: Mammography-Histopathological examination of breast mass specimens- polymerase chain reaction
Description: Mammography-Histopathological examination of breast mass specimens-Detection of long and short DNA fragments in serum using real-time quantitative polymerase chain reaction

Intervention type: DIAGNOSTIC_TEST
Intervention: Mammography-Histopathological examination of breast mass specimens- polymerase chain reaction
Description: Mammography-Histopathological examination of breast mass specimens-Detection of long and short DNA fragments in serum using real-time quantitative polymerase chain reaction
Study: NCT00217776

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Open Airways Educational Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Open Airways Educational Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Asthma Action Educational Intervention
Study: NCT03845361

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radial artery cannulation
Description: Radial artery cannulation
Study: NCT02703207

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV and /or oxygen
Description: supplemental oxygen will be applied to PAP/non-invasive positive pressure therapy
Study: NCT01985828

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated radiation therapy (IMRT)
Description: Per current standard of care

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated radiation therapy (IMRT)
Description: Per current standard of care
Study: NCT02287116

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Easy Flow system and INCA® nasal cannulae set
Study: NCT03295266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3866
Description: Single IV infusion of MK-3866 150 mg administered over 30 minutes at Hour 0 on Day 1 of treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3866
Description: Single IV infusion of MK-3866 150 mg administered over 30 minutes at Hour 0 on Day 1 of treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3866
Description: Single IV infusion of MK-3866 150 mg administered over 30 minutes at Hour 0 on Day 1 of treatment period.
Study: NCT04527848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: small amount of undiluted C3F8
Description: vitrectomy followed by peeling of the internal limiting membrane and, after that, intraocular gas injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: small amount of undiluted C3F8
Description: vitrectomy followed by peeling of the internal limiting membrane and, after that, intraocular gas injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: small amount of undiluted C3F8
Description: vitrectomy followed by peeling of the internal limiting membrane and, after that, intraocular gas injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: small amount of undiluted C3F8
Description: vitrectomy followed by peeling of the internal limiting membrane and, after that, intraocular gas injection
Study: NCT03001232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movement-oriented Dementia Care
Description: The intervention is a new multidisciplinary approach that focuses on optimizing physical activity and independence in daily care and activities. MDC intended to incorporate all persons surrounding the patients. The nursing staff was intensively trained by an expert in MDC, and played a central role in continuously stimulating patients to function as independently as possible. Geriatric physicians and physiotherapists advised the nursing staff about participants' medical and physical limitations to ensure safe stimulation. Consequently, a plan was created for each resident to determine the daily routines they were capable of performing themselves. Caregivers and volunteers were informed about the benefits of an active lifestyle during several open meetings.
Study: NCT03324503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid (prednisone or prednisolone)
Description: ≥ 30 mg/day prednisone or prednisolone taken orally as per local clinical practice of sarcoidosis initial induction therapy
Study: NCT02571946

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton beam therapy
Study: NCT00812188

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medium Dose UVA-1
Description: UVA-1 phototherapy treatment (60 J/cm2) three times per week for 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Dose UVA-1
Description: High dose (120 J/cm2)UVA-1 phototherapy three times per week for 12 weeks.
Study: NCT00194480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon
Description: Weekly injections of pegIntereferon
Study: NCT00058227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03395470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXL770
Description: MAD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXL770
Description: MAD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXL770
Description: MAD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXL770
Description: MAD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXL770
Description: MAD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXL770
Description: MAD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: MAD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: MAD
Study: NCT01394484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention I
Description: Four servings of dairy foods (milk and yogurt) per day for 42 days.
Study: NCT03395470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: MAD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: MAD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: MAD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: DDI
Study: NCT01550081

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rate of perceived exertion
Description: Exercise intensity controlled by Borg scale

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heart rate monitor
Description: Exercise intensity controlled by heart rate monitors
Study: NCT01394484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention I
Description: Four servings of dairy foods (milk and yogurt) per day for 42 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention II
Description: 1200 mg of supplemental calcium and 400 IU of vitamin D3 for 42 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention II
Description: 1200 mg of supplemental calcium and 400 IU of vitamin D3 for 42 days
Study: NCT02005315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vantictumab
Description: Administered intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vantictumab
Description: Administered intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vantictumab
Description: Administered intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel will be administered by intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel will be administered by intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel will be administered by intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered by intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered by intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered by intravenous (IV) infusion.
Study: NCT03734991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrexafungerp
Description: Ibrexafungerp 300 mg BID for 1 day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT03324399

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic
Description: a proprietary probiotic formulation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic
Description: a proprietary probiotic formulation
Study: NCT00346801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 100 mg by mouth (PO) twice daily for 5 days before beginning radiation therapy; continued 7 days per week throughout radiation treatment (about 7 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m\^2 IV over 60 minutes on Day 1, Weeks 2-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT-11
Description: 30 mg/m\^2 IV over 90 minutes on Day 1, Weeks 2-8, followed by cisplatin which will be infused for 60 minutes.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent Thoracic Radiation Therapy
Description: 63 Gy at 1.8 Gy/Fx in 35 Fractions over 7 weeks starting 2nd week of celebrex.
Study: NCT04596033

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-011
Description: Personalized neoantigen adoptive cell therapy (ACT)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-011
Description: Personalized neoantigen adoptive cell therapy (ACT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Cytokine
Study: NCT03334071

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: High intensity interspersed with short periods of exercise at a moderate intensity (aerobic interval training). We will also include resistance training in each session.~The supervised in-hospital exercise training sessions will last \<1 hour, exercise training intensities will be individually tailored to each CPET. Exercise training will involve repeated exercise bouts of 3 minutes at a moderate exercise intensity (80%AT) followed by 2 minutes of exercise at a high intensity (50%Δ) for a predetermined amount of time.~The home-based training programme will involve stair climbing (where possible) and brisk walking to achieve heart rates commensurate with those achieved during the in-hospital exercise training sessions.
Study: NCT00377312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parathyroid Hormone (1-34)
Description: PTH(1-34) IV given over a one week period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parathyroid Hormone (1-34)
Description: PTH(1-34) IV given over a one week period
Study: NCT00626158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000 mg/m2 IV day 1 of every cycle for 100 minutes (each cycle 14 days)
Study: NCT04596033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Cytokine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepletion drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepletion drug
Study: NCT04506749

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement consumption
Description: The consumption time was 56 days. Consumed 100 grams daily to consume during the day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplement consumption
Description: The consumption time was 56 days. Consumed 100 grams daily to consume during the day.
Study: NCT01279733

Intervention type: GENETIC
Intervention: Microarray analysis
Description: Microarray performed on prenatal specimen:~Fluorescence in-situ hybridization (FISH) or other standardized tests such as qPCR or MLPA will be performed on the fetal sample to confirm abnormal MA findings of known and unknown clinical significance which are discordant with CC findings, including anomalies normally detected by karyotyping.~Microarray analysis of DNA from parental blood samples will be used to determine whether CNVs detected in a fetal sample are also present in a healthy parent, in which case no further evaluation will take place, moreover any finding in a fetus which is duplicated in a parental microarray is considered to be confirmed.
Study: NCT04247399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation-based learning
Description: Pre-clinical simulation-based learning at Simbionix GI-mentor II virtual reality simulator and OGI CLA 4 phantom.
Study: NCT00826163

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Budesonide
Description: Inhaled budesonide 400 mcg twice a day for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Inhaled budesonide 400 mcg twice a day for 2 weeks
Study: NCT02568579

Intervention type: PROCEDURE
Intervention: blood sample/ stool sample
Description: blood sample to be done when possible with standard of care lab draw. Stool sample to be collected monthly at home.

Intervention type: PROCEDURE
Intervention: blood sample/ stool sample
Description: blood sample to be done when possible with standard of care lab draw. Stool sample to be collected monthly at home.
Study: NCT03331185

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Freeze Dried Bone Allograft
Description: Human derived bone particles used in oral and periodontal grafting procedures

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: L-PRF clot
Description: L-PRF is a second-generation platelet rich plasma obtained from autologous blood and contains several different growth factors, platelets and leucocytes in a complex fibrin matrix to accelerate the healing of soft and hard tissues.
Study: NCT01294501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication administration educational module
Description: The Research Assistant (RA) will enter the subject's language (English or Spanish), the type of medicine (tablet/capsule, liquid, or ointment) from the antibiotic prescription, and the frequency (once a day, twice a day, three times a day, four times a day) from the antibiotic prescription into the web-based educational module on medication administration so that a tailored module will be setup for the subject. The subject will then view the educational interactive module. After the subject is done with the module, the RA will administer a verbal post-test. The post-test will include questions on medication administration as well as questions on fever assessment and management.
Study: NCT00977769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbetocin 100 µg
Description: Hemodynamic effect of

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin 5 u
Description: Hemodynamic effect of

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (NaCl)
Description: Hemodynamic effect of
Study: NCT04588818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab plus Methotrexate
Description: Adalimumab 40 mg (≥30kg weight) or 20mg (\<30kg weight) subcutaneously every other week without loading dose.~Methotrexate(10 to 20 mg per square meter of body-surface area; maximum dose, 20 mg) .
Study: NCT01709305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin, 500 mg or 850 mg oral tablets, twice or three times a day (BID or TID) for a total dose of at least 1500 mg daily; administered with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin, 500 mg or 850 mg oral tablets, twice or three times a day (BID or TID) for a total dose of at least 1500 mg daily; administered with food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin, 500 mg or 850 mg oral tablets, twice or three times a day (BID or TID) for a total dose of at least 1500 mg daily; administered with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin, 500 mg or 850 mg oral tablets, twice or three times a day (BID or TID) for a total dose of at least 1500 mg daily; administered with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin, 100 mg oral tablet, once daily (QD); administered with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin, 100 mg oral tablet, once daily (QD); administered with or without food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin, 100 mg oral tablet, once daily (QD); administered with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin, 100 mg oral tablet, once daily (QD); administered with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: Acarbose, 50 mg oral tablets, TID (150 mg total daily dose); administered with the first bite of each main meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Repaglinide, 0.5 mg and/or 1 mg oral tablets, TID (up to 16 mg daily); administered within 30 minutes of each meal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride, 1 mg and/or 2 mg oral tablets, QD (up to 6 mg daily); administered before the first main meal of the day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide
Description: Gliclazide, 30 mg oral tablets, QD or BID (30 mg to 120 mg total daily dose); administered with meal.
Study: NCT00014196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT04444687

Intervention type: DIAGNOSTIC_TEST
Intervention: Test for SARS-CoV-2
Description: * As part of normal emergency evaluation due to symptoms or following standard operation procedure for patients heading to the operating theatre the status for SARS-CoV-2 is evaluated (gene expert, Roche)~* After intubation samples are acquired in the OR~  1. tracheal aspirate specimen directly after intubation (as part of standard operation procedures for CoVID-19 patients)~ 2. blood sample (as part of standard operation procedures for CoVID-19 patients)~ 3. fluid sample and smears from abdominal cavity as soon as this is accessed either by laparoscopy or laparotomy~ 4. Sample from laparoscopic smoke filters (Laparoshield™ Laparoscopic Smoke Filtration System)~* Fluid samples and smears are frozen at -80 degrees celcius for conservation in the OR.

Intervention type: DIAGNOSTIC_TEST
Intervention: Test for SARS-CoV-2
Description: * As part of normal emergency evaluation due to symptoms or following standard operation procedure for patients heading to the operating theatre the status for SARS-CoV-2 is evaluated (gene expert, Roche)~* After intubation samples are acquired in the OR~  1. tracheal aspirate specimen directly after intubation (as part of standard operation procedures for CoVID-19 patients)~ 2. blood sample (as part of standard operation procedures for CoVID-19 patients)~ 3. fluid sample and smears from abdominal cavity as soon as this is accessed either by laparoscopy or laparotomy~ 4. Sample from laparoscopic smoke filters (Laparoshield™ Laparoscopic Smoke Filtration System)~* Fluid samples and smears are frozen at -80 degrees celcius for conservation in the OR.
Study: NCT01550081

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heart rate monitor
Description: Exercise intensity controlled by heart rate monitors
Study: NCT00308087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (Leukine)
Description: Sargramostim 250 μg, administered subcutaneously (SC) 3 times weekly for 8 weeks, beginning at least 1 hour before the first dose of rituximab
Study: NCT02626221

Intervention type: OTHER
Intervention: Non Interventional Study
Description: Non Interventional Study